Different treatment types are often used, even for patients with the same clinical stage. Common treatment options for lung cancer include surgery, chemotherapy, radiation therapy, targeted treatment, and a combination of these.
Lung cancer cannot be cured. As long as lung cancer continues to cause death, as a result of metastasis, curative treatment is impossible. However, lung cancer treatment may be improved. Some people may have remission of symptoms.
Around 50 million Americans develop [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) each year, making lung cancer the most frequent cancer in US men. Approximately 20% of lung cancer deaths and 30% of lung cancer-related death in the United States occur to people with lung cancer.
Lung cancer is a malignancy of the lung. Lung cancer is the most common form of cancer affecting adults and is the most costly form of cancer in terms of lifetime costs. Smoking is often associated with the disease, and a number of other risk factors are being studied.
Pain, in one or both sides of the chest, is the most common symptom of lung cancer. In severe cases, it could be associated with breathlessness or hemoptysis.\n
There is a lot of information available about lung cancer risk factors. The main one which leads to the largest percentage of people dying from lung cancer is cigarette smoking. It is not only the number of cigarettes that causes lung cancer, but the length of time that a person have been smoking, for example, 5 pack-years with a 30 pack-year history. Smoking is the strongest and most prevalent risk factor for lung cancer. Even though less than 5 percent of lung cancer cases are caused by passive smoking, such as secondhand smoke in the home and workplace, research conducted shows an association between exposure to secondhand smoke and lung cancer risk. There is also a relationship between passive smoking and emphysema and COPD.
Results from a recent paper indicates no superiority of leucoselect phytosome over placebo tablets in reduction of pain and swelling rate. However, a possible clinical effect of leucoselect phytosome was evident in reduction of inflammation which may have led to pain and swelling in a quarter of patients.
Within the first two years following diagnosis, the tumor is almost always in localized or pT1. The likelihood of metastasis is highest at 4-6 months and decreases at 12 months. The chance of local/distant recurrence at 1 year is highest for T1b, whereas for nodular (pT2) lung cancer, the risk of recurrence is lowest.
Although it is still hard to prove these claims, these results are encouraging: a product that may potentially help women with breast cancer to avoid chemotherapy-induced ovarian damage and menopausal symptoms by keeping estrogen levels, and possibly also preventing premature menopause in some patients, at a reasonable profit.
The addition of phytosome in combination with other cancer treatments significantly (p < 0.01) reduced the number of patients who developed CIN 2/3 in comparison to placebo-treated patients. No significant difference was observed in terms of the progression rate, which were the primary outcome measures. No statistically significant difference (p = 0.10) was noticed in the median times to progression/recurrence or progression/recurrence/death of the treated patients compared with the placebo-treated group.
The phytosome-containing products are safe and well tolerated by healthy adults. Both the single and repeated administration of phytosome-containing products resulted in the reduction (≥80%) of the phytosome-induced erythema and skin swelling in healthy adults in a 7 days study.
Approximately 1 of 19 men and 1 of 44 women has lung cancer by age 65, and the average age at the time of diagnosis is between 56 and 57 years. This age range is broader than what has previously been reported. These data suggest that lung cancer is more common in this age range worldwide than previously assumed and warrant consideration of screening this group with lung cancer.